State-of-the-art technologies that measure multiple cellular aspects are at the heart of Insitro's efforts to accelerate drug development. Computational biology is key to translate measurements into actionable outcomes through clinically relevant insights derived from rich datasets generated in-house.
We are looking to hire a new team member with expertise in omics-based analyses, including deep understanding of single cell transcriptomics (e.g. perturbation screens), and fluent with state-of-the-art analysis techniques (e.g. large scale atlas integration). Your expertise will help the team navigate the complexities of transcriptomics data and ensure that the tools being developed are accurate and effective, and that the analyses are performed to the highest rigor and in line with best practices in the field.
In this role, you will directly impact all target prioritization efforts, advance our understanding of diseases and aid the development of new treatments. In general, as a computational biologist at insitro, you will be in charge of performing analysis of large scale datasets with an emphasis on multimodal measurements and data integration. You will utilize diverse machine learning and bioinformatic methods to perform downstream analysis and integrate omics, imaging, and human cohort data in order to extract insights about disease mechanisms. You will be part of a cross-functional team of life scientists, data scientists, bioengineers, software engineers, and machine learning scientists that strive to identify therapeutic targets and develop drugs of high efficacy and low toxicity.
You will be joining a vibrant biotech startup that has long-term stability, due to significant funding, and is in a high growth phase, and you will have many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro's culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Our target starting salary for successful US-based applicants for this role is $200,000 - $225,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.
Read Full Description